Capital Financial Planning LLC Purchases New Position in Stryker Co. (SYK)

Capital Financial Planning LLC purchased a new stake in Stryker Co. (NYSE:SYK) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 242 shares of the medical technology company’s stock, valued at approximately $38,000.

A number of other hedge funds have also modified their holdings of the business. Westside Investment Management Inc. increased its stake in shares of Stryker by 38.7% during the 4th quarter. Westside Investment Management Inc. now owns 233 shares of the medical technology company’s stock worth $37,000 after purchasing an additional 65 shares during the last quarter. DAVENPORT & Co LLC increased its stake in shares of Stryker by 1.6% during the 4th quarter. DAVENPORT & Co LLC now owns 4,340 shares of the medical technology company’s stock worth $680,000 after purchasing an additional 70 shares during the last quarter. Wedbush Securities Inc. increased its stake in shares of Stryker by 1.6% during the 4th quarter. Wedbush Securities Inc. now owns 4,497 shares of the medical technology company’s stock worth $705,000 after purchasing an additional 70 shares during the last quarter. Cornerstone Advisors Inc. increased its stake in shares of Stryker by 17.4% during the 3rd quarter. Cornerstone Advisors Inc. now owns 485 shares of the medical technology company’s stock worth $86,000 after purchasing an additional 72 shares during the last quarter. Finally, BKD Wealth Advisors LLC increased its stake in shares of Stryker by 2.0% during the 4th quarter. BKD Wealth Advisors LLC now owns 3,646 shares of the medical technology company’s stock worth $572,000 after purchasing an additional 72 shares during the last quarter. Hedge funds and other institutional investors own 75.28% of the company’s stock.

Shares of SYK stock opened at $194.44 on Friday. The stock has a market cap of $73.87 billion, a P/E ratio of 26.60, a P/E/G ratio of 2.43 and a beta of 0.88. The company has a quick ratio of 1.41, a current ratio of 2.02 and a debt-to-equity ratio of 0.72. Stryker Co. has a 52 week low of $144.75 and a 52 week high of $198.75.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 29th. The medical technology company reported $2.18 EPS for the quarter, topping the consensus estimate of $2.15 by $0.03. The business had revenue of $3.80 billion during the quarter, compared to the consensus estimate of $3.73 billion. Stryker had a net margin of 26.12% and a return on equity of 27.60%. On average, research analysts forecast that Stryker Co. will post 8.13 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 1.07%. The ex-dividend date is Thursday, March 28th. Stryker’s dividend payout ratio is currently 28.45%.

Several research analysts have recently weighed in on SYK shares. Morgan Stanley lowered their price objective on shares of Stryker from $212.00 to $197.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 2nd. SunTrust Banks boosted their price objective on shares of Stryker to $205.00 and gave the stock a “positive” rating in a research note on Monday, February 4th. Royal Bank of Canada boosted their price objective on shares of Stryker from $184.00 to $204.00 and gave the stock an “outperform” rating in a research note on Monday, March 11th. Credit Suisse Group upgraded shares of Stryker to an “outperform” rating in a research note on Thursday, January 31st. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $205.00 price objective on shares of Stryker in a research note on Friday, March 1st. Seven analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $190.46.

In other Stryker news, VP Katherine Ann Owen sold 29,247 shares of the business’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $185.62, for a total value of $5,428,828.14. Following the completion of the sale, the vice president now owns 11,131 shares of the company’s stock, valued at approximately $2,066,136.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Yin C. Becker sold 15,240 shares of the business’s stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $198.03, for a total transaction of $3,017,977.20. Following the completion of the sale, the vice president now directly owns 16,577 shares of the company’s stock, valued at approximately $3,282,743.31. The disclosure for this sale can be found here. Insiders sold a total of 85,385 shares of company stock valued at $15,821,091 in the last three months. Insiders own 7.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was reported by Stock Observer and is the property of of Stock Observer. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.thestockobserver.com/2019/03/24/capital-financial-planning-llc-purchases-new-position-in-stryker-co-syk.html.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Read More: Why do companies pay special dividends?

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.